Cardiometabolic

ACC/AHA guidelines are reshaping US payer policies, expanding coverage and access to breakthrough cardiovascular therapies like SGLT2 and PCSK9 inhibitors. But costs, red tape, and uneven access still stand in the way.

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.